- Trials with a EudraCT protocol (1,346)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (164)
1,346 result(s) found for: lymphoma.
Displaying page 40 of 68.
EudraCT Number: 2020-001856-16 | Sponsor Protocol Number: 35RC17_9804_REVOLUMHOD | Start Date*: 2020-09-08 | |||||||||||
Sponsor Name:Rennes University Hospital | |||||||||||||
Full Title: Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumor VOLUME in Patients Treated for Conventional HODgkin's Lymphoma | |||||||||||||
Medical condition: Refractory Hodgkin Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005702-22 | Sponsor Protocol Number: IELSG39 | Start Date*: 2013-03-17 |
Sponsor Name:INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP | ||
Full Title: International prospective Phase 2 trial addressing the efficacy of first-line Chlamydophila psittaci-eradicating therapy with protracted administration of doxycycline followed by eradication moni... | ||
Medical condition: Patients with newly diagnosed Ocular Adnexal Marginal Zone Lymphoma (OAMZL) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-000097-56 | Sponsor Protocol Number: HOVON110 | Start Date*: 2013-06-11 | |||||||||||
Sponsor Name:HOVON Foundation | |||||||||||||
Full Title: ReBeL study: a randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients ≥ 18 years with relapsed follicular lymphoma A HOVON/GLSG/NCRI study | |||||||||||||
Medical condition: Follicular Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004493-96 | Sponsor Protocol Number: CT-P10-3.3 | Start Date*: 2014-03-21 | ||||||||||||||||
Sponsor Name:CELLTRION, Inc. | ||||||||||||||||||
Full Title: A Phase 1/3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan, E... | ||||||||||||||||||
Medical condition: Advanced Follicular Lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) ES (Completed) GR (Completed) IT (Completed) PT (Completed) BG (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-002302-30 | Sponsor Protocol Number: 83/2004/U/Sper | Start Date*: 2004-07-20 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: FMZ Fludarabine, Mitoxantrone, Zevalin regimen a phase II study as front-line treatment in indolent non-follicular non-Hodgkins lymphoma patients | |||||||||||||
Medical condition: Confirmed histologic diagnosis according to the REAL classification of B-cell indolent lymphoma including small lymphocytic, immunocytoma, and marginal zone lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004377-84 | Sponsor Protocol Number: GO27834 | Start Date*: 2013-04-11 | ||||||||||||||||||||||||||
Sponsor Name:Genentech, Inc. | ||||||||||||||||||||||||||||
Full Title: A randomized, open-label, multicenter, phase II trial evaluating the safety and activity of pinatuzumab vedotin (DCDT2980S) in combination with rituximab or polatuzumab vedotin (DCDS4501A) in combi... | ||||||||||||||||||||||||||||
Medical condition: Follicular Non-Hodgkin’s Lymphoma (FL); Diffuse Large B-Cell Lymphoma (DLBCL) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) IT (Completed) NL (Completed) FR (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-001052-39 | Sponsor Protocol Number: DSHNHL2006-1A | Start Date*: 2010-04-14 |
Sponsor Name:University Medicine Goettingen | ||
Full Title: Auto-versus Allotransplantation in T-NHL - Autologous or allogeneic transplantation following conventional chemotherapy in younger patients (18-60 yrs.) with mature (peripheral) T-cell lymphoma | ||
Medical condition: Peripheral (mature) T-cell lymphoma, first diagnosis, ALK-negative | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-006028-41 | Sponsor Protocol Number: BER-PUM-01 | Start Date*: 2022-02-21 |
Sponsor Name:Pomorski Uniwersytet Medyczny w Szczecinie | ||
Full Title: Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas- BERUBICIN | ||
Medical condition: Primary central nervous system lymphoma (PCNSL) and secondary non-Hodgkin's lymphoma with central nervous system involvement (NHL-CNSI) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002261-22 | Sponsor Protocol Number: KTE-C19-107 | Start Date*: 2018-09-11 | |||||||||||
Sponsor Name:Kite Pharma, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7) | |||||||||||||
Medical condition: Relapsed/Refractory Diffuse Large B cell Lymphoma (r/r DLBCL). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) BE (Completed) IT (Completed) ES (Ongoing) FR (Completed) SE (Completed) AT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000704-28 | Sponsor Protocol Number: GCP#05.01.020 | Start Date*: 2016-06-16 | ||||||||||||||||||||||||||
Sponsor Name:Gamida Cell Ltd | ||||||||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, versus Unmanipulated Umbilical Cord... | ||||||||||||||||||||||||||||
Medical condition: High risk haematological malignancies | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) PT (Completed) FR (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-000087-29 | Sponsor Protocol Number: MO28543 | Start Date*: 2013-08-26 | ||||||||||||||||
Sponsor Name:F. Hoffmann- La Roche Ltd. | ||||||||||||||||||
Full Title: A multicenter, open-label, single-arm, phase IIIb, international study evaluating the safety of Obinutuzumab alone or in combination with chemotherapy in patients with previously untreated or relap... | ||||||||||||||||||
Medical condition: Chronic lymphocytic leukemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) DE (Completed) ES (Completed) FI (Completed) LV (Completed) SI (Completed) IE (Completed) PT (Completed) EE (Completed) GR (Completed) SE (Completed) PL (Completed) SK (Completed) BE (Completed) LT (Completed) FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-005843-40 | Sponsor Protocol Number: PXD101-CLN-19 | Start Date*: 2008-11-11 | |||||||||||
Sponsor Name:Spectrum Pharmaceuticals Inc. | |||||||||||||
Full Title: A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma | |||||||||||||
Medical condition: Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) FR (Completed) IT (Completed) NL (Completed) BE (Completed) DE (Completed) ES (Completed) HU (Completed) SK (Completed) PL (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003539-22 | Sponsor Protocol Number: ZETAL 07 | Start Date*: 2007-11-08 | |||||||||||
Sponsor Name:GIMURELL | |||||||||||||
Full Title: Two repeated doses of Yttrium-90 labeled Ibritumomab-Tiuxetan (Zevalin) as salvage treatment for patients with relapsed or refractory aggressive B-cell lymphoma: a phase II study. | |||||||||||||
Medical condition: Patients with B-DLCL relapsed or refractory after first line of therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004682-11 | Sponsor Protocol Number: AUTO3-DB1 | Start Date*: 2017-07-19 | |||||||||||||||||||||||||||||||
Sponsor Name:Autolus Limited | |||||||||||||||||||||||||||||||||
Full Title: A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 with Anti PD-1 Antibody in Patients wi... | |||||||||||||||||||||||||||||||||
Medical condition: Relapsed or refractory Diffuse Large B Cell Lymphoma (DLBCL) and large B cell lymphoma subsets | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003931-40 | Sponsor Protocol Number: BRD/05/95 | Start Date*: 2006-04-20 |
Sponsor Name:University College London | ||
Full Title: Phase ll Trial of Fludarabine & Cyclophosphamide followed by Thalidomide for Angioimmunoblastic Lymphoma | ||
Medical condition: Angioimmunoblastic T-cell lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-002197-34 | Sponsor Protocol Number: 04/Q1104/27 | Start Date*: 2004-12-14 |
Sponsor Name:University College London | ||
Full Title: A phase III multicentre randomised clinical trial comparing rituximab with CHOP given every 14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly diagnosed d... | ||
Medical condition: Newly diagnosed diffuse large B cell non-Hodgkin's lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-002521-23 | Sponsor Protocol Number: FOLLREC3 | Start Date*: 2006-10-13 | |||||||||||
Sponsor Name:G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI | |||||||||||||
Full Title: Phase II study of VELCADE in combination with Rituximab in patients with relapsed or progressed Non Hodgkin's Follicular Lymphoma | |||||||||||||
Medical condition: relapsed or progressed Follicular non Hodgkin's Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003077-25 | Sponsor Protocol Number: VELCADE-MALT- LYMPHOM | Start Date*: 2005-09-13 |
Sponsor Name:AKH Vienna | ||
Full Title: PHASE II TRIAL OF BORTEZOMIB (VELCADE®) IN PATIENTS WITH ADVANCED OR RELAPSED LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT) | ||
Medical condition: patients with MALT-lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-002103-32 | Sponsor Protocol Number: 50-03B | Start Date*: 2005-03-02 |
Sponsor Name:GELA-Recherche Clinique | ||
Full Title: Phase III multicentre open-label randomised study of ICE plus Rituximab (R-ICE) versus DHAP plus Rituximab (R-DHAP) in previously treated patients with CD 20 positive diffuse large B-cell lymphoma,... | ||
Medical condition: CD 20 positive diffuse large B cell lymphoma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-007698-22 | Sponsor Protocol Number: R2-CHOP | Start Date*: 2008-07-10 |
Sponsor Name:GELARC | ||
Full Title: A PHASE IB/II STUDY OF ESCALATING DOSES OF REVLIMID IN ASSOCIATION WITH R-CHOP (R2-CHOP) IN THE TREATMENT OF B-CELL LYMPHOMA | ||
Medical condition: B cell lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
